J. Goldman & Co’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

J. Goldman & Co’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$255K	Buy	+2,000	New	+$250K	0.01%	580
2025 Q1	–	Sell	-16,834	Closed	-$1.5M	–	668
2024 Q4	$1.52M	Buy	+16,834	New	+$1.63M	0.04%	297
2022 Q4	–	Sell	-3,750	Closed	-$304K	–	507
2022 Q3	$297K	Buy	+3,750	New	+$316K	0.01%	318
2021 Q4	–	Sell	-3,972	Closed	-$499K	–	450
2021 Q3	$499K	Buy	3,972 +1,093	+38%	+$141K	0.03%	273
2021 Q2	$390K	Sell	2,879 -700	-20%	-$92K	0.02%	338
2021 Q1	$485K	Buy	3,579 +25	+0.7%	+$3.74K	0.02%	365
2020 Q4	$500K	Buy	+3,554	New	+$455K	0.03%	278
2018 Q1	–	Sell	-15,000	Closed	-$1.37M	–	446
2017 Q4	$1.27M	Buy	+15,000	New	+$1.26M	0.07%	221

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

J. Goldman & Co's XBI Position: Q1 2026 in Review

J. Goldman & Co opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q1 2026: 2,000 shares worth $255K. The stake represents 0.01% of the portfolio and ranks #580 among its holdings. This is a return to the name: J. Goldman & Co previously reported a position in XBI as recently as Q4 2024.

J. Goldman & Co first reported a position in XBI in Q4 2017 and has held it in 8 quarters since. The position peaked at $1.52M in Q4 2024. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

J. Goldman & Co held 2,000 shares of State Street SPDR S&P Biotech ETF worth $255K as of Q1 2026.
State Street SPDR S&P Biotech ETF was a new J. Goldman & Co position in Q1 2026.
State Street SPDR S&P Biotech ETF made up 0.01% of J. Goldman & Co's portfolio in Q1 2026, its #580 holding.
J. Goldman & Co first reported a position in State Street SPDR S&P Biotech ETF in Q4 2017 and has held it in 8 quarters since.
J. Goldman & Co's State Street SPDR S&P Biotech ETF position peaked at $1.52M in Q4 2024.
813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.